Caricamento...
Combined MAPK pathway and HDAC inhibition breaks melanoma
In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat NRAS- and NF1-driven tumors, with MGMT expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination...
Salvato in:
| Pubblicato in: | Cancer Discov |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6446927/ https://ncbi.nlm.nih.gov/pubmed/30936219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0069 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|